Beyond Sunscreen and Retinoids: Will Patients Benefit From An Antioxidant Serum?
The antioxidant treatment choices are numerous leading to confusion in product claims for patients and for clinicians, with a paucity of clinical data. Do patients really benefit from the use of antioxidants? Is every antioxidant serum the same? What clinical scenarios will provide optimal clinical outcomes?
- Discuss the deleterious effects of free radicals on the skin and the aging process
- Review the existing literature of use of antioxidants in skincare, providing insight to the question whether antioxidant serums actually influence the way our skin ages.
- Discuss the importance of clinical data to support serum selection.
Beyond the Skin: The Feasibility and Value of Systematic Screening for Psoriatic Arthritis
Dermatologists are the gatekeeper to identifying patients with early signs of PsA. However, many dermatologists do not routinely consider screening for possible signs and symptoms of psoriatic arthritis – a common psoriasis comorbidity that causes irreversible joint damage and aggravates co-morbidities.
The data from Phase 1 of the PsA Screening Project will be presented. In an initial assessment survey of 52 Canadian dermatologists, only 17% will screen their moderate-to-severe psoriasis patients for psoriatic arthritis at every follow-up visit. When screening for PsA, only 9% of respondents rely on a validated screening questionnaire. When PsA is suspected, over 50% of dermatologists will refer to a rheumatologist reflecting a need for greater comfort in managing PsA patients in dermatology practice and when appropriate, initiating a referral to rheumatologist. The PsA Screening Project had dermatologists from across the country screen patients using 3 different tools, to establish which tool type was preferred, and what barriers exist that prevent them from adequately screening.
Session Learning Objectives:
- Recognize the impact of frequent screening for PsA on early detection
- Demonstrate the value of using a standardized screening tool for PsA in dermatology practice
- Consider best practices for implementation of systematic screening to improve patient outcomes
Skin Barrier Differences in Various Racial/Ethnic Canadian Populations - A Consensus
The Canadian population is diverse with a growing multicultural population. Currently, there are persistent disparities in the care and treatment of skin conditions across different ethnic groups. We will present the first consensus statements on skin barrier differences in various racial/ethnic Canadian populations from the country’s leading ethnodermatology experts. Furthermore, this symposium will review and discuss the benefits of ceramide-containing skin care in diverse populations. Finally, there will be a discussion on next steps and future directions to consider in order to champion and improve equitable dermatological for care for all.
- Present 5 statements of the consensus from Canada’s leading ethnodermatology experts addressing skin barrier differences in various racial/ethnic Canadian populations
- Discuss the relevance of skincare containing ceramides (cleansers and moisturizers) in various racial/ethnic Canadian populations
- Explore next steps and future directions to champion equitable dermatological care for all
The Science of Sensitive Skin: Identifying Patients and the 5 signs of Skin Sensitivity
This session is designed to discussion Sensitive Skin; the prevalence, the triggers and the way in which patients are identified. During this session we will also introduce the 5 signs of skin sensitivity and discuss how Cetaphil, the brand can help support patients with sensitive skin. Furthermore, we will dive into clinical data to support the science behind Cetaphil for sensitive skin.
Objective(s) of the session:
- How do we describe “Sensitive Skin”?
- Identifying Patients with Sensitive Skin: What are the 5 Signs of Skin Sensitivity?
- Cetaphil: Enhanced Formulas. New Look.
- Clinical data to support the use of Cetaphil for sensitive skin
What’s New in Type 2?
Type 2 Inflammation Is the Predominant Inflammatory pathway driving Atopic dermatitis, and its understanding in AD and other Dermatological conditions continues to evolve. There are novel concepts where research is progressing such as barrier function, microbiome and neuroimmune mechanisms of itch. The arrival of novel agents specifically targeting T2i was a breakthrough around five years ago. We can now understand the long-term impact of specifically targeting the T2i pathway. There are also new dermatological diseases beyond AD where we now know T2i is playing an important role in pathophysiology.
- Review research updates on barrier dysfunction and in the pathophysiology of AD
- Review latest data in long term control of moderate to severe AD
- Review Type 2 inflammation as a therapeutic target in dermatologic diseases outside of AD
Innovations in Topical Therapy: The Role of Vehicle in Treatment Decisions
This session will present audience members with a brief overview around the importance of vehicle formulation in immunodermatologic treatment. The content of the session will focus on current topical therapies as well potential future vehicle formulations while considering the clinical implications of the differences between various vehicle formulations. The session will consider the role of vehicle formulation across different regions of the body and examine factors that may influence patient adherence to therapy.
- To discuss the importance of vehicle in immunodermatologic treatment
- To examine opportunities for advancements with current topical therapies
- To consider potential future vehicle formulation(s)
Skin Health and Oat Therapy
- Identify the components and the multifaceted benefits of colloidal oatmeal and its effect on the moisture barrier
- Recognize the clinical research highlighting the benefits of colloidal oatmeal in various skin conditions
Treating Sun Damage With Sunlight: PDT
- Review PDT protocols for the treatment of actinic keratosis,
- Discuss the ideal patient for daylight PDT treatment,
- Review practical treatment considerations with daylight PDT
Lunch Break / Visit Virtual Exhibits
The A,B,C's of Sculptra: Activation, Biostimulation and Collagen
- Understand what Sculptra is and how it works to stimulate collagen growth
- Identify who the ideal patient is - age, demographic, skin type;
- Provide an overview of the data to support Sculptra and clinical results
Be Informed about Recent Psoriasis Treatment Advances
- Analyze the bimekizumab clinical trial program, focusing on the efficacy and safety of bimekizumab in patients with moderate-to-severe psoriasis.
- Share first-hand experience with bimekizumab from Canadian trialists.
- Explore perspectives on the future landscape of psoriasis management in Canada.
The Dynamic Skin Barrier and Why Formulation Matters
When you think of the skin what comes to mind? What active ingredients do you recommend to support your patients skin health? The skin barrier proactively works to protect the skin's moisture balance and integrity through several integrated functions. This webinar evolves the skin barrier conversation beyond a brick-and-mortar structure to the sophisticated and complex Dynamic Skin Barrier while reviewing evidence-based ingredient science that matters to you and your patients.
Objectives(s) of the session:
- Evaluate the skin barrier as a dynamic sophisticated structure
- Analyze the research on products, ingredients and technologies that are gentle, effective and support the dynamic skin barrier
- Describe criteria to consider when making product, ingredient, regimen recommendations to patients